Teva’s Generic Irbesartan Deserves 180-Day Exclusivity Because Of Review Delays, FDA Says
This article was originally published in The Pink Sheet Daily
Lupin Pharmaceuticals had filed a citizen petition arguing that Teva was not entitled to the first-mover 180-day exclusivity because it failed to get tentative approval within 30 months, but FDA said that it had changed its criteria and requested additional testing.
You may also be interested in...
Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.